What is Veristat?
Founded in 1994, Veristat operates as a full-service, science-focused clinical research organization (CRO). The company specializes in supporting clinical trials and regulatory submissions for a diverse clientele, including pharmaceutical, biotechnology, and medical device firms. Veristat's expertise lies in navigating the complexities of drug development and device commercialization, providing critical services that facilitate the journey from research to market approval. Its long-standing presence in the industry underscores a deep understanding of regulatory landscapes and clinical trial management.
How much funding has Veristat raised?
Veristat has raised a total of $2M across 1 funding round:
Debt
$2M
Debt (2020): $2M with participation from PPP
Key Investors in Veristat
PPP
Public-Private Partnership
What's next for Veristat?
The substantial enterprise-level funding positions Veristat for accelerated growth and strategic expansion. This capital infusion is likely to be directed towards enhancing its service portfolio, investing in advanced technologies for clinical trial management, and potentially broadening its global reach. The company's focus on science-driven solutions suggests a continued commitment to supporting innovative therapies and medical devices through rigorous clinical research and regulatory guidance. Future developments may include strategic partnerships or acquisitions aimed at further solidifying its market position as a leading CRO.
See full Veristat company page
